Related Experiment Videos

Partial protective effect of MK-801 on MPTP-induced reduction of striatal dopamine in mice

A Tabatabaei1, T L Perry, S Hansen

  • 1Department of Pharmacology and Therapeutics, University of British Columbia, Vancouver, Canada.

Neuroscience Letters
|July 20, 1992
PubMed

Insights

MK-801, an N-methyl-D-aspartate (NMDA) receptor antagonist, protected striatal dopamine levels against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in mice. This suggests NMDA receptors play a role in MPTP-induced neurotoxicity.

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a neurotoxin that selectively destroys dopaminergic neurons, causing Parkinsonism.
  • N-methyl-D-aspartate (NMDA) receptors are implicated in various neurological processes, including excitotoxicity.

Purpose of the Study:

  • To investigate the neuroprotective potential of MK-801, an NMDA receptor antagonist, against MPTP-induced dopaminergic neurotoxicity.
  • To determine if NMDA receptor blockade affects striatal dopamine levels following MPTP exposure.

Main Methods:

  • C57 BL/6 mice were administered MK-801 prior to and following MPTP injection.
  • Striatal dopamine levels were measured 28 days post-MPTP administration.
  • Monoamine oxidase-B (MAO-B) inhibition by MK-801 was assessed.

Main Results:

  • Mice treated with MK-801 exhibited significantly higher striatal dopamine levels compared to those receiving MPTP alone.
  • MK-801 did not inhibit MAO-B activity.
  • The neuroprotective effect of MK-801 was observed 28 days after MPTP treatment.

Conclusions:

  • NMDA receptor antagonism with MK-801 confers significant protection against MPTP-induced reduction of striatal dopamine.
  • These findings suggest that NMDA receptors are involved in the neurotoxic mechanisms of MPTP.
  • Targeting NMDA receptors may represent a therapeutic strategy for MPTP-induced neurotoxicity.

Related Concept Videos